Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation
- 1 December 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 101 (12) , 2931-2938
Abstract
Background Low tacrolimus concentrations have been associated with higher risk of acute rejection, particularly within African American (AA) kidney transplant recipients; little is known about intrapatient tacrolimus variabilities impact on racial disparities. Methods Ten year, single-center, longitudinal cohort study of kidney recipients. Intrapatient tacrolimus variability was assessed using the coefficient of variation (CV) measured between 1 month posttransplant and the clinical event, with a comparable period assessed in those without events. Pediatrics, nontacrolimus/mycophenolate regimens, and nonrenal transplants were excluded. Multivariable Cox regression models were used to analyze data. Results One thousand four hundred eleven recipients were included (54.4% AA) with 39 521 concentrations used to assess intrapatient tacrolimus CV. Overall, intrapatient tacrolimus CV was higher in AAs versus non-AAs (39.9 ± 19.8 % vs 34.8 ± 15.8% P < 0.001). Tacrolimus variability was a significant risk factor for deleterious clinical outcomes. A 10% increase in tacrolimus CV augmented the risk of acute rejection by 20% (adjusted hazard ratio, 1.20, 1.13-1.28; P < 0.001) and the risk of graft loss by 30% (adjusted hazard ratio, 1.30, 1.23-1.37; P < 0.001), with significant effect modification by race for acute rejection, but not graft loss. High tacrolimus variability (CV >40%) was a significant explanatory variable for disparities in AAs; the crude relative risk of acute rejection in AAs was reduced by 46% when including tacrolimus variability in modeling and reduced by 40% for graft loss. Conclusions These data demonstrate that intrapatient tacrolimus variability is strongly associated with acute rejection in AAs and graft loss in all patients. Tacrolimus variability is a significant explanatory variable for disparities in AA recipients.Keywords
This publication has 52 references indexed in Scilit:
- Mobile Health Medication Adherence and Blood Pressure Control in Renal Transplant Recipients: A Proof-of-Concept Randomized Controlled TrialJMIR Research Protocols, 2013
- Dosing equation for tacrolimus using genetic variants and clinical factorsBritish Journal of Clinical Pharmacology, 2011
- CYP3A5 Genotype Is Not Related to the Intrapatient Variability of Tacrolimus ClearanceTherapeutic Drug Monitoring, 2011
- CYP3A5*3 Genotype Associated With Intrasubject Pharmacokinetic Variation Toward Tacrolimus in Bioequivalence StudyTherapeutic Drug Monitoring, 2010
- Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant RecipientsAmerican Journal of Transplantation, 2009
- African American Kidney Transplantation SurvivalDrugs, 2009
- Associations of Characteristics of Renal Transplant Recipients With Clinicians’ Perceptions of Adherence to Immunosuppressant TherapyTransplantation, 2007
- Disparities in Solid Organ Transplantation for Ethnic Minorities: Facts and SolutionsAmerican Journal of Transplantation, 2006
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- RACIAL DIFFERENCES IN RENAL TRANSPLANTATION AFTER IMMUNOSUPPRESSION WITH TACROLIMUS VERSUS CYCLOSPORINE1Transplantation, 1998